title: [Advanced hepatocellular carcinoma: value of systemic chemotherapy combining adriamycin, amiodarone and 5-fluorouracil].
authors.forename: L
authors.initials: L
authors.lastname: Bedenne
authors.forename: B
authors.initials: B
authors.lastname: Chauffert
authors.forename: B
authors.initials: B
authors.lastname: Lorcerie
authors.forename: J
authors.initials: J
authors.lastname: Faivre
authors.forename: P
authors.initials: P
authors.lastname: Hillon
authors.forename: C
authors.initials: C
authors.lastname: Klepping
authors.forename: F
authors.initials: F
authors.lastname: Martin
mesh_terms: D000328:Adult; D000368:Aged; D000638:Amiodarone / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D004317:Doxorubicin; D000638:Amiodarone; D005472:Fluorouracil
vernacular_title: Carcinomes hépatocellulaires évolués: intérêt d'une chimiothérapie systémique associant adriamycine, amiodarone et 5 fluoro-uracile.